Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran

Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

As quoted in the press release:

“We are encouraged by these data from the APOLLO study on the effects of patisiran on measures of cardiac disease in hATTR amyloidosis patients with polyneuropathy,” said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. “These data support the hypothesis that patisiran may favorably impact certain cardiac manifestations of hATTR amyloidosis. Accordingly, we believe these results support further study of the effects of patisiran on cardiac features of hATTR amyloidosis.”

“Our publication highlights the potential for patisiran to favorably impact certain cardiac manifestations of hATTR amyloidosis,” said Scott D. Solomon M.D., Professor of Medicine, Brigham and Women’s Hospital, Harvard Medical School, lead author of the paper. “The results on exploratory endpoints of NT-proBNP – an independent predictor of survival in patients with ATTR amyloidosis – and certain echocardiographic measures of cardiac structure and function are encouraging. Together, these data support the therapeutic potential of patisiran in patients with cardiac involvement due to hATTR amyloidosis, where there is a substantially reduced lifespan and limited treatment options.”

Click here to read the full press release.